Clinical trials: Cancer, Thyroid
Indeterminate Thyroid Nodules
Management of Indeterminate Thyroid Nodules Across Different World Regions
Thyroid carcinoma (TC) is the most common endocrine malignancy, affecting 0.2-1.5% of individuals worldwide. The rising incidence rate of TC is mostly related to the expanding use of high-quality imaging techniques, with an…
- Trial name
- NCT05851404
- Testing
- Thyroidectomy
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- University of Cagliari
Thyroid Cancer
Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
1. Determine the frequency of utilizing single and multiple doses of radioactive iodine (RAI) in treatment of differentiated thyroid cancer. 2.
- Trial name
- NCT06134830
- Testing
- RAI
- Volunteers
- 100 people
- Sponsor
- Assiut University
Thyroid Nodule (Benign)
US-guided RFA vs MWA in the Treatment of Benign Thyroid Nodules
To evaluate the clinical outcomes of RFA and MWA for benign thyroid nodules treatment
- Trial name
- NCT05758038
- Testing
- Radiofrequency ablation/Microwave ablation
- Volunteers
- 50 people
- Sponsor
- Assiut University
Thyroid Carcinoma, Thyroid Papillary Carcinoma
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
In the last decades, thyroid cancer incidence has continuously increased all over the world, almost exclusively due to a sharp rise in the incidence of the papillary histologic subtype, which has the highest incidence of…
- Conditions
- Thyroid Carcinoma, Thyroid Papillary Carcinoma, Multinodular Goiter, Adolescent, Solitary Thyroid Nodule
- Trial name
- NCT04411290
- Testing
- Total thyroidectomy (TT)
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Umraniye Education and Research Hospital
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial…
- Trial name
- NCT01424878
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Follicular Thyroid Cancer, SEER Database Analysis
Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC
This study aims to thoroughly examine survival disparities in patients with T3 or T4 stage follicular thyroid carcinoma (FTC) as classified by the AJCC staging system.
- Trial name
- NCT06437873
- Testing
- Total Thyroidectomy (TT), Radioactive iodine treatment(RAIT)
- Volunteers
- 2,957 people, healthy volunteers welcome
- Sponsor
- Dezhou Hospital Qilu Hospital of Shandong University
Thyroid Abnormalities, Thyroid
Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration
The goal of this observational study is to evaluate the diagnostic accuracy and clinical workflow integration of an ultrasound intelligent agent (UIA) for thyroid disease management in a real-world multicenter setting.
- Conditions
- Thyroid Abnormalities, Thyroid, Thyroid Cancer
- Trial name
- NCT07296575
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Nanchang University
Differentiated Thyroid Cancer, Pediatric Cancer
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy.
- Conditions
- Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
- Trial name
- NCT05783323
- Testing
- Larotrectinib monotherapy, 131I therapy
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Thyroid Neoplasms
Study of Clinical Outcomes of Thyroid Cancer
The Italian Thyroid Cancer Observatory (ITCO) repository was established to collect data on thyroid cancer management in a prospective and consecutive series of newly-diagnosed patients, enrolled in centers uniformly distributed…
- Trial name
- ITCO (NCT04031339)
- Testing
- Standard treatment
- Where
- 35 sites in Italy
- Volunteers
- 15,000 people
- Sponsor
- University of Roma La Sapienza
Thyroid Nodule
Role of TIRADS and Bethesda Scoring Systems in Management of Thyroid Nodules
role of TIRADS and Bethesda scoring system in management of thyroid nodules as these methods are ultrasound clasification that helps increase the diagnostic effectiveness of thyroid nodules and reduces the use of preopeative FNA…
- Trial name
- NCT06417463
- Testing
- thyroidectomy opeartion
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sohag University
Papillary Thyroid Cancer
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
The incidence of papillary thyroid cancer (PTC) has been on the rise in recent years, and 20%-50% of PTC patients will have lymph node metastasis.
- Trial name
- NCT06286631
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Papillary Thyroid Carcinoma
APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.
To determine the improvement in diagnosis of papillary carcinoma by detecting mutation V600E BRAF in retrospective cases with inconclusive cytologic diagnosis (categories III, IV and V of Bethesda System)
- Trial name
- NCT02323724
- Testing
- BRAF V600E mutation by pyrosequencing technique
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Corporacion Parc Tauli
Thyroid Cancer
The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer
The purpose of this study is to determine whether the use of honey mouthwashes in the prevention of salivary side effects of 131I (radioiodine) therapy.
- Trial name
- NCT01833650
- Testing
- thymus honey mouthwash
- Where
- Cyprus
- Volunteers
- 120 people
- Sponsor
- Cyprus University of Technology
Thyroid Carcinoma, Pediatric Cancer
Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy
This study aims to define the optimal surveillance strategy for children exposed to radiotherapy by assessing the incidence, risk factors, and timing of thyroid nodules and differentiated thyroid cancer.
- Trial name
- NCT07473518
- Where
- 2 sites in Italy
- Volunteers
- 2,550 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Thyroid Cancer
Three-pronged Centralized Molecular Analysis to Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
This multi-center study aims at NTRK fusion testing of all patients with advanced thyroid cancer (any histotype and regardless of stage).
- Trial name
- NTRK (NCT05796258)
- Testing
- NTRK fusion assessment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Regina Elena Cancer Institute